Loading
institutionsInstitution
Shaare Zedek Medical Center
Jerusalem's community-facing academic hospital, home of ESMO-MCBS architect Nathan Cherny and leading BRCA population screening research.
Also called: Sha'are ZedekShaarei Tzedek
Overview
Founded in 1902, Shaare Zedek Medical Center is one of Jerusalem's two large academic hospitals. Nathan Cherny, who directs its cancer pain and palliative medicine service, chairs the working group behind the ESMO Magnitude of Clinical Benefit Scale used to grade the value of cancer treatments, and Ephrat Levy-Lahad's Medical Genetics Institute has led studies showing the feasibility of population-based BRCA1/2 screening in Ashkenazi Jewish women. The hospital's oncology and haematology institutes provide comprehensive treatment, and the centre has a strong tradition in supportive and palliative care, medical ethics and access to medicines research.
Location
Jerusalem, IL
Type
hospital · Hebrew University of Jerusalem
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#184 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
- Palliative medicine and ESMO-MCBS
- Medical genetics and BRCA population screening
- Oncology and haematology institutes
Alberto Gabizon
Oncologist, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School
Liposomal drug deliveryPharmacokinetics of nanomedicinesOvarian and breast cancer
The clinician half of the partnership that turned a liposome chemistry idea into Doxil, and the person who did the trials that showed it behaved differently in patients from free doxorubicin.
Ephrat Levy-Lahad
Director, Medical Genetics Institute, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School
Cancer geneticsBRCA1 and BRCA2Population genetic screening
Produced the evidence that made Israel the first country to offer BRCA testing to a whole population group, by measuring cancer risk in carriers found through healthy men rather than through cancer clinics.
Ofer Merin
Director General
Cardiothoracic surgeryHospital leadershipDisaster medicine
Cardiac surgeon and former IDF field hospital commander who serves as Director General of Shaare Zedek Medical Center in Jerusalem.
Rachel Michaelson-Cohen
Gynaecologist and medical geneticist, Shaare Zedek Medical Center; chair of the Israeli Consortium harmonising national BRCA carrier care
Hereditary breast and ovarian cancerRisk-reducing surgeryHealth policy
Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding.
Nathan Cherny
Director, Cancer Pain and Palliative Medicine, Shaare Zedek Medical Center; Chair, ESMO-MCBS Working Group
Palliative medicineValue assessment of cancer drugsEthics
Created the ESMO Magnitude of Clinical Benefit Scale, the standard tool for grading how much a cancer drug really helps.
Similar pages
- TermFounder variant
Shares Rachel Michaelson-Cohen, Ephrat Levy-Lahad, Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2, Inherited risk is mostly unidentified.
- PersonEitan Friedman
Shares Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- IdeaTreat wasting like sepsis: a trigger, a bundle, an audit
Shares Nathan Cherny, Pain relief and palliative care are unavailable to most, Geriatric assessment.
- PersonYechezkel Barenholz
Shares Hebrew University of Jerusalem, Hadassah Medical Center, Ovarian cancer.
- IdeaOncology teams order germline tests; tele-genetic counsellors handle the results
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- IdeaPower trials to detect a benefit patients would value, not the smallest detectable one
Shares Nathan Cherny, European Society for Medical Oncology (ESMO), Prices and value.
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.